专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

41. 发明申请

US20100204233A1 IMIDAZOLE DERIVATIVES 审中-公开
标题翻译：咪唑衍生物
公开(公告)号：US20100204233A1
公开(公告)日：2010-08-12
申请号：US12765898
申请日：2010-04-23
申请人： Guido Galley , Katrin Groebke Zbinden , Roger Norcross , Henri Stalder
发明人： Guido Galley , Katrin Groebke Zbinden , Roger Norcross , Henri Stalder
IPC分类号： A61K31/4164 , A61K31/5377 , A61K31/4178 , C07D413/10 , C07D405/12 , C07D233/64 , C07D233/58 , A61P25/00 , A61P25/22 , A61P25/24 , A61P25/16
CPC分类号： C07D233/64
摘要： The invention relates to imidazole derivatives which have a good affinity to the trace amine associated receptors (TAARs), especially for TAAR1.The invention also relates to a pharmaceutically-suitable acid-addition salt of the above compound.The invention further relates to a composition comprising an imidazole derivative as described above, or a pharmaceutically-suitable acid-addition salt thereof, and to processes for preparing such compounds.
摘要翻译：本发明涉及对微量胺相关受体（TAAR）具有良好亲和力的咪唑衍生物，特别是TAAR1。本发明还涉及上述化合物的药学上合适的酸加成盐。本发明还涉及包含如上所述的咪唑衍生物或其药学上合适的酸加成盐的组合物及其制备方法。

42. 发明申请

US20090036420A1 BENZAMIDE DERIVATIVES AND THEIR USE FOR TREATING CNS DISORDERS 审中-公开
标题翻译：苯扎林衍生物及其用于治疗中枢神经系统疾病的用途
公开(公告)号：US20090036420A1
公开(公告)日：2009-02-05
申请号：US12180566
申请日：2008-07-28
申请人： Guido Galley , Katrin Groebke Zbinden , Roger Norcross , Henri Stalder
发明人： Guido Galley , Katrin Groebke Zbinden , Roger Norcross , Henri Stalder
IPC分类号： A61K31/397 , A61K31/55 , A61K31/5377 , A61K31/5375 , A61K31/505 , A61K31/4545 , A61K31/445 , A61K31/4427 , A61K31/4439 , A61K31/44 , A61K31/426 , A61K31/421 , A61K31/415 , A61K31/382 , A61K31/165 , A61K31/34 , C07D413/02 , C07D233/08 , C07D401/02 , C07D265/30 , C07D239/02 , C07D211/68 , C07D211/32 , C07D405/02 , C07D213/56 , C07D275/02 , C07D263/34 , C07D231/02 , C07D207/46 , C07D205/02 , C07D337/08 , C07D307/02 , C07C323/41 , C07C233/88 , A61P25/18 , A61P25/28 , A61P25/24 , A61P25/16
CPC分类号： A61K31/166 , A61K31/167 , C07C233/65 , C07C233/75 , C07C235/56 , C07C237/40 , C07C255/57 , C07C311/16 , C07C311/21 , C07C317/44 , C07D205/06 , C07D211/14 , C07D213/82 , C07D231/12 , C07D263/32 , C07D275/06 , C07D295/155 , C07D295/26 , C07D401/04
摘要： The present invention relates to methods of treating CNS disorders with a compound of formula I wherein X, R1, R2, R3, R4, R5, R6, R7, and R8 are as defined in the specification and pharmaceutically acceptable acid addition salts thereof.
摘要翻译：本发明涉及用式I化合物治疗CNS障碍的方法，其中X，R 1，R 2，R 3，R 4，R 5，R 6，R 7和R 8如本说明书中所定义及其药学上可接受的酸加成盐。

43. 发明申请

US20090012138A1 4-IMIDAZOLINES 失效
标题翻译： 4-咪唑啉
公开(公告)号：US20090012138A1
公开(公告)日：2009-01-08
申请号：US12146497
申请日：2008-06-26
申请人： Guido Galley , Katrin Groebke Zbinden , Roger Norcross , Henri Stalder
发明人： Guido Galley , Katrin Groebke Zbinden , Roger Norcross , Henri Stalder
IPC分类号： A61K31/4164 , C07D233/10
CPC分类号： C07D233/06 , C07D233/12 , C07D233/22 , C07D233/24
摘要： The present invention relates to compounds of formula wherein R1, R2, X, Y and Ar are as defined herein and to their pharmaceutically active salts, with the exclusion of the racemic compound 4-benzyl-4,5-dihydro-1H-imidazole or its tautomer (CAS 131548-83-9). Compounds of formula I have a good affinity to the trace amine associated receptors (TAARs), especially for TAAR1 and are useful for the treatment of depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder (ADHD), stress-related disorders, psychotic disorders such as schizophrenia, neurological diseases such as Parkinson's disease, neurodegenerative disorders such as Alzheimer's disease, epilepsy, migraine, hypertension, substance abuse and metabolic disorders such as eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy consumption and assimilation, disorders and malfunction of body temperature homeostasis, disorders of sleep and circadian rhythm, and cardiovascular disorders.
摘要翻译：本发明涉及下式的化合物，其中R 1，R 2，X，Y和Ar如本文所定义及其药学活性盐，排除外消旋化合物4-苄基-4,5-二氢-1H-咪唑或其互变异构体（CAS 131548-83-9）。式I化合物对微量胺相关受体（TAAR）具有良好的亲和力，尤其对于TAAR1，可用于治疗抑郁症，焦虑障碍，双相情感障碍，注意缺陷多动障碍（ADHD），应激相关疾病，精神病性诸如精神分裂症，神经系统疾病如帕金森病，神经变性疾病如阿尔茨海默氏病，癫痫，偏头痛，高血压，药物滥用和代谢性疾病如进食障碍，糖尿病，糖尿病并发症，肥胖症，血脂异常，能量消耗和同化障碍等疾病，体温平衡紊乱和失眠，睡眠障碍和昼夜节律，以及心血管疾病。

44. 发明申请

US20080119535A1 AMINOMETHYL-4-IMIDAZOLES 失效
标题翻译：氨基甲基-4-咪唑烷
公开(公告)号：US20080119535A1
公开(公告)日：2008-05-22
申请号：US11872203
申请日：2007-10-15
申请人： Guido Galley , Annick Goergler , Katrin Groebke Zbinden , Roger Norcross , Henri Stalder
发明人： Guido Galley , Annick Goergler , Katrin Groebke Zbinden , Roger Norcross , Henri Stalder
IPC分类号： A61K31/417 , C07D233/64 , C07D401/12 , C07D403/12 , C07D413/12 , A61P25/00 , A61P25/16 , A61P25/28 , A61P25/06 , A61P3/10
CPC分类号： C07D233/64
摘要： The present invention relates to amino-4-methyl imidazoles and pharmaceutically-acceptable salts thereof.The compound may be used for the treatment of depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder (ADHD), stress-related disorders, psychotic disorders such as schizophrenia, neurological diseases such as Parkinson's disease, neurodegenerative disorders such as Alzheimer's disease, epilepsy, migraine, hypertension, substance abuse and metabolic disorders such as eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy consumption and assimilation, disorders and malfunction of body temperature homeostasis, disorders of sleep and circadian rhythm, and cardiovascular disorders.
摘要翻译：本发明涉及氨基-4-甲基咪唑及其药学上可接受的盐。该化合物可用于治疗抑郁症，焦虑障碍，双相情感障碍，注意力缺陷多动障碍（ADHD），应激相关疾病，精神病性精神障碍如精神分裂症，神经系统疾病如帕金森病，神经变性疾病如阿尔茨海默病，癫痫，偏头痛，高血压，药物滥用和代谢障碍如进食障碍，糖尿病，糖尿病并发症，肥胖症，血脂异常，能量消耗和同化障碍，体温平衡紊乱和失调，睡眠和昼夜节律紊乱以及心血管疾病。

45. 发明申请

US20070197620A1 Methods for treating CNS disorders with bicyclo-substituted 2-imidazoline and 2-imidazoles 审中-公开
标题翻译：用双环取代的2-咪唑啉和2-咪唑治疗CNS障碍的方法
公开(公告)号：US20070197620A1
公开(公告)日：2007-08-23
申请号：US11655375
申请日：2007-01-19
申请人： Guido Galley , Katrin Groebke Zbinden , Roger Norcross , Henri Stalder
发明人： Guido Galley , Katrin Groebke Zbinden , Roger Norcross , Henri Stalder
IPC分类号： A61K31/415 , C07D207/18 , C07D233/58
CPC分类号： C07D233/56 , A61K31/4166 , A61K31/4174 , A61K31/4709 , C07D233/06 , C07D233/20 , C07D233/22 , C07D233/64 , C07D401/04 , C07D401/06 , C07D405/04
摘要： The present invention relates to a method for treating a disorder selected from depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder, stress-related disorders, psychotic disorders such as schizophrenia, neurological diseases such as Parkinson's disease, neurodegenerative disorders such as Alzheimer's disease, epilepsy, migraine, hypertension, substance abuse and metabolic disorders such as eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy consumption and assimilation, disorders and malfunction of body temperature homeostasis, disorders of sleep and circadian rhythm, and cardiovascular disorders which comprises administering to an individual a therapeutically effective amount of a compound of formula I wherein R1, R2, Q, W, X, Y, m, and n are as defined in the specification d or not; and their pharmaceutically active salts, racemic mixtures, enantiomers, optical isomers and tautomeric forms. The invention also relates to novel compounds of formula I, compositions containing them, and methods for their preparation.
摘要翻译：本发明涉及一种治疗选自抑郁症，焦虑障碍，双相情感障碍，注意缺陷多动障碍，应激相关障碍，精神病性精神分裂症，神经性疾病如帕金森病，神经变性疾病如阿尔茨海默病，癫痫，偏头痛，高血压，药物滥用和代谢紊乱，如进食障碍，糖尿病，糖尿病并发症，肥胖症，血脂异常，能量消耗和同化障碍，体温平衡紊乱和失调，睡眠和昼夜节律紊乱以及心血管其包括向个体施用治疗有效量的式I化合物，其中R 1，R 2，Q，W，X，Y，m和n 在规范d中是否定义; 及其药物活性盐，外消旋混合物，对映异构体，光学异构体和互变异构体形式。本发明还涉及式I的新化合物，含有它们的组合物及其制备方法。

46. 发明申请

US20070197569A1 Method for treating central nervous system disorders with substituted 2-imidazoline derivatives 审中-公开
标题翻译：用取代的2-咪唑啉衍生物治疗中枢神经系统障碍的方法
公开(公告)号：US20070197569A1
公开(公告)日：2007-08-23
申请号：US11655484
申请日：2007-01-19
申请人： Marius Hoener , Sabine Kolczewski , Henri Stalder
发明人： Marius Hoener , Sabine Kolczewski , Henri Stalder
IPC分类号： A61K31/415 , A61K31/505 , C07D233/44 , C07D239/02
CPC分类号： A61K31/4164 , A61K31/4168 , A61K31/4174
摘要： The present invention relates to a method for treating depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder (ADHD), stress-related disorders, psychotic disorders such as schizophrenia, neurological diseases such as Parkinson's disease, neurodegenerative disorders such as Alzheimer's disease, epilepsy, migraine, hypertension, substance abuse and metabolic disorders such as eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy consumption and assimilation, disorders and malfunction of body temperature homeostasis, disorders of sleep and circadian rhythm, and cardiovascular disorders which comprises administering to an individual a therapeutically effective amount of a compound of formula I wherein R, X, A, and n are as defined in the specification and pharmaceutically active salts, racemic mixtures, enantiomers, optical isomers and tautomeric forms thereof.
摘要翻译：本发明涉及一种治疗抑郁症，焦虑障碍，双相情感障碍，注意缺陷多动障碍（ADHD），应激相关疾病，精神病如精神分裂症，神经系统疾病如帕金森病，神经变性疾病如阿尔茨海默病，癫痫，偏头痛，高血压，药物滥用和代谢障碍如进食障碍，糖尿病，糖尿病并发症，肥胖症，血脂异常，能量消耗和同化障碍，体温平衡紊乱和失调，睡眠和昼夜节律紊乱以及心血管疾病其包括向个体施用治疗有效量的式I化合物，其中R，X，A和n如说明书中所定义，以及药学活性盐，外消旋混合物，对映异构体，旋光异构体及其互变异构形式。

47. 发明授权

US5260310A Oxetanone compounds and pharmaceutical compositions containing them 失效
标题翻译：氧杂环丁酮化合物和含有它们的药物组合物
公开(公告)号：US5260310A
公开(公告)日：1993-11-09
申请号：US928907
申请日：1992-08-12
申请人： Romano Derungs , Hans P. Marki , Henri Stalder , Andre Szente
发明人： Romano Derungs , Hans P. Marki , Henri Stalder , Andre Szente
IPC分类号： C07D305/12 , C07D405/12 , A61K31/365
CPC分类号： C07D405/12 , C07D305/12
摘要： Novel compounds of the formula ##STR1## wherein Q, R.sup.1 and R.sup.2 are described herein, are disclosed along with pharmaceutical compositions, methods of use, and process for producing compounds of formula I which starts from the corresponding .beta.-hydroxycarboxylic acids.
摘要翻译：本文所述的其中Q，R 1和R 2的新颖化合物与药物组合物，使用方法以及从相应的β-羟基羧酸开始制备式I化合物的方法一起公开。

48. 发明申请

US20120196903A1 2-AMINOOXAZOLINES AS TAAR1 LIGANDS 有权
标题翻译： 2-AMINOOXAZOLINES as TAAR1 LIGANDS
公开(公告)号：US20120196903A1
公开(公告)日：2012-08-02
申请号：US13426736
申请日：2012-03-22
申请人： Guido Galley , Katrin Groebke Zbinden , Roger Norcross , Henri Stalder
发明人： Guido Galley , Katrin Groebke Zbinden , Roger Norcross , Henri Stalder
IPC分类号： A61K31/421 , C07D413/04 , A61K31/4439 , A61P25/24 , A61P25/22 , A61P25/00 , A61P25/18 , A61P25/16 , A61P25/28 , A61P25/08 , A61P25/06 , A61P25/30 , A61P3/00 , A61P3/10 , A61P3/04 , A61P3/06 , A61P9/00 , C07D263/28
CPC分类号： C07D263/28 , C07D413/04 , C07D413/06 , C07D413/12 , C07F7/0812
摘要： The invention relates to compounds of formula I wherein X, Y, R′, R2, and n are as defined herein or to a pharmaceutically suitable acid addition salt thereof. The invention also relates to pharmaceutical compositions containing such compounds and methods for the treatment of diseases related to the biological function of the trace amine associated receptors, which diseases include depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder, stress-related disorders, psychotic disorders, schizophrenia, neurological diseases, Parkinson's disease, neurodegenerative disorders, Alzheimer's disease, epilepsy, migraine, substance abuse and metabolic disorders, eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy consumption and assimilation, disorders and malfunction of body temperature homeostasis, disorders of sleep and circadian rhythm, and cardiovascular disorders.
摘要翻译：本发明涉及其中X，Y，R'，R 2和n如本文所定义或其药学上合适的酸加成盐的式I化合物。本发明还涉及含有这些化合物的药物组合物和用于治疗与微量胺相关受体的生物功能相关的疾病的方法，所述疾病包括抑郁症，焦虑障碍，双相情感障碍，注意缺陷多动障碍，应激相关疾病，精神病，精神分裂症，神经系统疾病，帕金森病，神经变性疾病，阿尔茨海默病，癫痫，偏头痛，药物滥用和代谢紊乱，进食障碍，糖尿病，糖尿病并发症，肥胖症，血脂异常，能量消耗和同化障碍，体温稳态，睡眠障碍和昼夜节律，以及心血管疾病。

49. 发明申请

US20110281871A1 TAAR1 LIGANDS 审中-公开
标题翻译： TAAR1配偶
公开(公告)号：US20110281871A1
公开(公告)日：2011-11-17
申请号：US13190510
申请日：2011-07-26
申请人： Guido Galley , Katrin Groebke Zbinden , Roger Norcross , Henri Stalder
发明人： Guido Galley , Katrin Groebke Zbinden , Roger Norcross , Henri Stalder
IPC分类号： A61K31/5377 , A61K31/4545 , A61K31/4439 , A61K31/44 , A61K31/166 , C07D401/14 , C07D401/04 , C07D401/12 , C07D413/04 , C07D213/78 , C07C233/66 , A61K31/496 , C07D405/14
CPC分类号： C07D213/80 , C07C233/66 , C07D213/82 , C07D235/08 , C07D401/12 , C07D405/12
摘要： The invention relates to a compound of formula wherein R1, R2, X, L, W, n, and o are defined herein and to pharmaceutically suitable acid addition salts thereof, with the exception of the following compounds 6-(4-methyl-piperazin-1-yl)-N-phenethyl-nicotinamide (CAS 199478-31-4), N-(3,4-dichloro-benzyl)-3-fluoro-benzamide (CAS 424815-98-5), N-(4-chloro-benzyl)-3-fluoro-benzamide (CAS 544661-83-8), N-(3-chloro-benzyl)-3-fluoro-benzamide (CAS 796051-07-5), and N-phenethyl-6-phenylamino-nicotinamide (CAS 571913-74-1). The compounds of formula I have a good affinity to the trace amine associated receptors (TAARs), especially for TAAR1 and are useful for the treatment of CNS disorders.
摘要翻译：本发明涉及下式的化合物，其中R 1，R 2，X，L，W，n和o在本文中定义及其药学上合适的酸加成盐，但以下化合物6-（4-甲基 - 哌嗪（CAS 199478-31-4），N-（3,4-二氯 - 苄基）-3-氟 - 苯甲酰胺（CAS 424815-98-5），N-（4 - 氯 - 苄基）-3-氟 - 苯甲酰胺（CAS 544661-83-8），N-（3-氯 - 苄基）-3-氟 - 苯甲酰胺（CAS 796051-07-5）和N-苯乙基-6 - 苯基氨基 - 烟酰胺（CAS 571913-74-1）。式I化合物对微量胺相关受体（TAAR）具有良好的亲和力，特别是TAAR1，可用于治疗CNS疾病。

50. 发明授权

US07875645B2 Method for the treatment of CNS disorders with substituted 2-imidazoles or imidazole derivatives 失效
标题翻译：用取代的2-咪唑或咪唑衍生物治疗CNS障碍的方法
公开(公告)号：US07875645B2
公开(公告)日：2011-01-25
申请号：US11655468
申请日：2007-01-19
申请人： Guido Galley , Katrin Groebke Zbinden , Marius Hoener , Sabine Kolczewski , Roger Norcross , Henri Stalder
发明人： Guido Galley , Katrin Groebke Zbinden , Marius Hoener , Sabine Kolczewski , Roger Norcross , Henri Stalder
IPC分类号： A61K31/415 , C07D233/56
CPC分类号： C07D233/06 , A61K31/4164 , A61K31/4178 , C07D233/20 , C07D233/22 , C07D233/56 , C07D233/64 , C07D401/10 , C07D403/06 , C07D405/06 , C07D409/06
摘要： The present invention relates a method for treating depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder, stress-related disorders, psychotic disorders such as schizophrenia, neurological diseases such as Parkinson's disease, neurodegenerative disorders such as Alzheimer's disease, epilepsy, migraine, hypertension, substance abuse and metabolic disorders such as eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy consumption and assimilation, disorders and malfunction of body temperature homeostasis, disorders of sleep and circadian rhythm, and cardiovascular disorders which comprises administering to an individual a therapeutically effective amount of a compound of formula I wherein R, R1, R2, A and n are as defined in the specification and to their pharmaceutically active salts. The invention also relates to novel compounds of formula I, pharmaceutical compositions containing them, and methods for their preparation.
摘要翻译：本发明涉及治疗抑郁症，焦虑障碍，双相情感障碍，注意缺陷多动障碍，应激相关障碍，精神病如精神分裂症，神经系统疾病如帕金森病，神经变性疾病如阿尔茨海默病，癫痫，偏头痛，高血压，药物滥用和代谢障碍如进食障碍，糖尿病，糖尿病并发症，肥胖症，血脂异常，能量消耗和同化障碍，体温平衡紊乱和失调，睡眠和昼夜节律紊乱以及心血管疾病，其包括给予个体治疗有效量的式I化合物，其中R，R 1，R 2，A和n如说明书中所定义，并且其药物活性盐。本发明还涉及式I的新型化合物，含有它们的药物组合物及其制备方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式